Provide global leadership in sleep medicine and non-invasive ventilation based on innovative technology advancing the diagnosis, treatment, and management of sleep-disordered breathing.
Corporate Aims and Objectives
We are a global leader in the development, manufacturing and marketing of innovative medical products for the treatment and management of respiratory disorders, with a focus on sleep-disordered breathing.
We sell a comprehensive range of products in more than 70 countries worldwide through direct offices and a network of distributors.
We are committed to advancing innovative technology in sleep and respiratory medicine and commercialising innovative products incorporating these technologies on a global basis. In reaching our goals, we will at all times act ethically in dealing with both customers and employees.
History
ResMed (ASX: RMD and NYSE: RMD) is a leading developer, manufacturer and marketer of products for the screening, treatment and long-term management of sleep-disordered breathing (SDB) and other respiratory disorders.
Formed in 1989
Primary purpose was to commercialize a device for treating obstructive sleep apnea (OSA), the most common type of SDB*
We have maintained our focus on SDB. There is greater public and physician awareness
Operations have grown dramatically via the introduction of highly innovative product lines
We operate in more than 70 countries via direct offices and a network of distributors
*Nasal continuous positive airway pressure (CPAP) therapy was developed in 1981 by Professor Colin Sullivan and colleagues (University of Sydney, Australia) and provided the first successful non-invasive treatment of OSA.
